BioWorld

April 10, 2002

Roche Paying Isotechnika Up To $215M For Transplantation Drug

Hoffmann-La Roche Inc. agreed to spend upward of $215 million in a global partnership with Isotechnika Inc. to develop a transplantation drug with blockbuster potential. (BioWorld Today) Read More

AEterna Seeks Acquisitions In Cancer Following C$57M Financing

Subterranean Naked Mole-Rats’ All-Purpose Incisors Neuronally Sensed In Huge Neocortex Area

Hyseq Raises $15M Privately To Develop Proprietary Drugs

Other News To Note

ImClone Presents Preclinical Data Of Erbitux In Combination Study

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...